Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Bucillamine

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Revive Therapeutics Provides Bucillamine Nerve Agent Study Update
    Revive Therapeutics Provides Bucillamine Nerve Agent Study Update

    31 Oct 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/10/31/2972503/0/en/Revive-Therapeutics-Provides-Update-on-Research-Study-Evaluating-Bucillamine-for-Nerve-Agent-Exposure.html

    GLOBENEWSWIRE
    31 Oct 2024
    Share Share
    Revive Focuses On Bucillamine For Infectious Diseases
    Revive Focuses On Bucillamine For Infectious Diseases

    18 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/09/18/2948084/0/en/Revive-Therapeutics-Announces-Strategic-Focus-on-Bucillamine-for-Infectious-Diseases-and-Medical-Countermeasures.html

    GLOBENEWSWIRE
    18 Sep 2024
    Share Share
    Revive Therapeutics Updates On Bucillamine Research For Nerve Agents
    Revive Therapeutics Updates On Bucillamine Research For Nerve Agents

    28 Aug 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/08/28/2936877/0/en/Revive-Therapeutics-Provides-Update-on-Research-Study-Evaluating-Bucillamine-for-Nerve-Agent-Exposure-and-Expansion-into-Viral-Infections.html

    GLOBENEWSWIRE
    28 Aug 2024
    Share Share
    Revive Therapeutics Updates On Bucillamine For Nerve Agent Exposure Study
    Revive Therapeutics Updates On Bucillamine For Nerve Agent Exposure Study

    02 Jul 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/07/02/2907735/0/en/Revive-Therapeutics-Provides-Update-on-Research-Study-Evaluating-Bucillamine-for-Nerve-Agent-Exposure.html

    GLOBENEWSWIRE
    02 Jul 2024
    Share Share
    Revive Therapeutics Updates On FDA Meeting For Long COVID Study
    Revive Therapeutics Updates On FDA Meeting For Long COVID Study

    12 Jun 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/06/12/2897596/0/en/Revive-Therapeutics-Provides-Update-on-FDA-Type-C-Meeting-for-Clinical-Study-of-Bucillamine-to-Treat-Long-COVID.html

    GLOBENEWSWIRE
    12 Jun 2024
    Share Share
    Revive Requests FDA Meeting for Bucillamine Long COVID Study
    Revive Requests FDA Meeting for Bucillamine Long COVID Study

    23 Apr 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/04/23/2867498/0/en/Revive-Therapeutics-Announces-Type-C-Meeting-Request-Granted-by-FDA-for-Clinical-Study-of-Bucillamine-to-Treat-Long-COVID.html

    GLOBENEWSWIRE
    23 Apr 2024
    Share Share